Life-changing therapies

Innovative medicines pipeline
Macrocycle discovery platform
Collaborate with Polyphor

Latest news

• Polyphor and the University of Zurich announces publication in 'Nature' of the unique mechanism of action of a new class of antibiotics.

• Polyphor to present at the H.C. Wainwright Global Investment Conference

See all news

Meet us at

November 10, 2019	H.C. Wainwright 5th Annual Israel Conference in Tel-Aviv, Israel Perion CEO Doron Gerstel and CFO Maoz Sigron will be attending
November 20 – 21, 2019	Jefferies 2019 London Healthcare Conference Waldorf Hilton | Aldwych | London WC2B 4DD | UK

 

 

Event calendar

Innovative medicines pipeline

CXCR4 antagonist

Balixafortide (POL6326) – for novel immune-oncology agent for combination therapy

Fast Track Designation granted by FDA

Phase III

Antibiotics

Murepavadin (POL7080) – Pseudomonas infections

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

OMPTA platform –  targeting Gram-negative resistant pathogens

Lead preclinical compound: POL7306

 

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Inhaled elastase inhibitor

POL6014 – Cystic Fibrosis

Outlicensed to Santhera Pharmaceuticals 14.02.2018

Phase I

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Macrocycle discovery platform

New modalities to address challenging biological targets

Learn more